欢迎来到CSNpharm!产品仅用于科研!

400-920-2911 sales@csnpharm.cn

0

OXTR

OXTR

货号 产品名 CAS号 信息
CSN27602 SHR1653 2231770-73-1 SHR1653 is a highly potent oxytocin receptor antagonist with excellent blood-brain barrier penetration. It might be beneficial for the treatment of CNS-related premature ejaculation.
CSN20503 Retosiban 820957-38-8 Retosiban is an oral active, potent and selective, sub-nanomolar (Ki = 0.65 nM) oxytocin receptor antagonist with > 1400-fold selectivity over the related vasopressin receptors. Retosiban inhibits the procontractile effect of stretch on human myometrium and prevent stretch-induced stimulation of human myometrial contractility.
CSN18548 Cligosiban 900510-03-4 PF-3274167 is a high-affinity nonpeptide oxytocin receptor (OTR) antagonist, with Ki of 9.5 nM.
CSN11642 (S)-N-((S)-1-((2-Amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-((S)-sec-butyl)-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide 50-56-6 Oxytocin is a mammalian neurohypophysial hormone which stimulates uterine contraction and lactation.
CSN18363 Oxytocin acetate 6233-83-6 Oxytocin acetate is a mammalian neurohypophysial hormone and its actions are mediated by specific, high-affinity oxytocin receptors and ligand of oxytocin receptor.
CSN18244 OT-R antagonist 2 364071-16-9 OT-R antagonist 2 is a nonpeptide low molecular weight OT-R antagonist.
CSN18245 OT-R antagonist 1 364071-17-0 OT-R antagonist 1 is a potent and selective nonpeptide low molecular weight OT-R antagonist.
CSN22478 OT antagonist 3 925703-75-9 OT antagonist 3 is an oxytocin (OT) antagonist extracted from patent WO2007017752A1.
CSN22477 OT antagonist 1 479080-38-1 OT antagonist 1 (Compound 4) is a potent, selective Oxytocin antagonist with a Ki of 50 nM.
CSN10118 Lysipressin 50-57-7 Lysipressin is an antidiuretic hormone that havs been found in pigs and some marsupial families. It can induce contraction of the rabbit urinary bladder smooth muscle.
CSN25228 (S)-2-(Dimethylcarbamothioyl)-N-(2-methyl-4-(1-methyl-1,4,5,10-tetrahydrobenzo[b]pyrazolo[3,4-e][1,4]diazepine-5-carbonyl)benzyl)pyrrolidine-1-carboxamide 2,2,2-trifluoroacetate   2245072-21-1 LIT-001 is the first nonpeptide oxytocin receptor agonist.
CSN22443 L-368,899 HCl 160312-62-9 L-368,899 HCl is a potent, selective, orally bioavailable, non-peptide oxytocin receptor antagonist, with IC50s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively, used as a tocolytic agent.
CSN22158 Epelsiban 872599-83-2 GSK 557296 is a potent, selective and orally bioavailable oxytocin receptor antagonist, with a pKi of 9.9 for human oxytocin receptor.
CSN17014 Carbetocin 37025-55-1 Carbetocin is an obstetric drug used to control postpartum hemorrhage and bleeding after giving birth and an agonist at peripheral oxytocin receptors.
CSN24204 (S)-1-((3R,6S,9S,12S,15S)-6-(2-Amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-((S)-sec-butyl)-15-(4-methoxybenzyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosane-3-carbonyl)-N-((S)-1-((2-amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)pyrrolidine-2-carboxamide acetate 1936459-26-5 Carbetocin is an obstetric drug used to control postpartum hemorrhage and bleeding after giving birth and an agonist at peripheral oxytocin receptors.
CSN29535 (S)-N-((S)-5-Amino-1-((2-amino-2-oxoethyl)amino)-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-((S)-sec-butyl)-16-(4-ethoxybenzyl)-10-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide acetate 914453-95-5 Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.
<< PREV 1 NEXT >>
联系
我们